De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care

Documenti analoghi

• De Novo Letermovir for Cytomegalovirus Prophylaxis in High‐Risk Liver Transplant Recipients
  di: Hanna L. Kleiboeker, et al.
  Pubblicazione: (2025)
• Cytomegalovirus Post‐Prophylaxis Surveillance in High‐Risk Kidney and Liver Recipients Prevents CMV End‐Organ Disease and Ganciclovir‐Resistance
  di: Margaret R. Jorgenson, et al.
  Pubblicazione: (2024)
• Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant
  di: Suneri J. Amin, et al.
  Pubblicazione: (2025)
• Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients
  di: John‐Anthony Coppola, et al.
  Pubblicazione: (2025)
• Real‐World Off‐Label Use of Letermovir Prophylaxis for Cytomegalovirus Prevention in Non‐Kidney Solid Organ Transplant Recipients: Outcomes, Safety, and Review of Literature
  di: Abdallah Mughrabi, et al.
  Pubblicazione: (2026)